Chargement en cours...
Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world
Alemtuzumab is a humanized monoclonal antibody approved for the treatment of relapsing-remitting multiple sclerosis (RRMS), given as two annual courses on five consecutive days at baseline and on three consecutive days 12 months later. Here we provide an update on the long-term efficacy and safety o...
Enregistré dans:
| Publié dans: | Ther Adv Neurol Disord |
|---|---|
| Auteurs principaux: | , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
SAGE Publications
2017
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5607928/ https://ncbi.nlm.nih.gov/pubmed/28966663 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756285617722706 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|